Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

✍ Scribed by Rao N. V. S. Mamidi; Steve Weng; Susan Stellar; Charles Wang; Ning Yu; Tony Huang; Alfred P. Tonelli; Michael F. Kelley; Anthony Angiuoli; Man-Cheong Fung

• Publisher: Springer
• Year: 2010
• Tongue: English
• Weight: 278 KB
• Volume: 66
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-010-1406-x